Subscribe To
Annexon to report archer phase 2 trial results in geographic atrophy at asrs 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) — ...
July 24, 2023, 10:30 am
Bvi expands iol capacity with new state of the art facility in belgium
WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic ...
July 18, 2023, 9:00 am
Aldeyra therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalm...
June 15, 2023, 10:49 am
Outlook therapeutics: august pdufa may be a buy with some caveats
OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's ...
June 10, 2023, 1:06 am
Outlook therapeutics® reports financial results for second quarter fiscal year 2023 and provides corporate update
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ...
May 15, 2023, 12:05 pm
The global hospital equipment and supplies market size was valued at usd 39.21 billion in 2022 and is projected to reach usd 110.63 billion by 2030, growing at a cagr of 12.21% from 2023 to 2030.| dat
According to a market research study published by Contrive Datum Insights, The medical equipment market includes various segments such as orthopaedic ...
May 10, 2023, 4:00 am
The global hospital equipment and supplies market size was valued at usd 39.21 billion in 2022 and is projected to reach usd 110.63 billion by 2030, growing at a cagr of 12.21% from 2023 to 2030.| dat
According to a market research study published by Contrive Datum Insights, The medical equipment market includes various segments such as orthopaedic ...
May 10, 2023, 4:00 am
The global hospital equipment and supplies market size was valued at usd 39.21 billion in 2022 and is projected to reach usd 110.63 billion by 2030, growing at a cagr of 12.21% from 2023 to 2030.| dat
According to a market research study published by Contrive Datum Insights, The medical equipment market includes various segments such as orthopaedic ...
May 10, 2023, 4:00 am
Societal cdmo selected by xequel bio to provide cdmo services to support ongoing clinical development of inexin™
Activities Focused on Xequel’s ophthalmic Solution Containing aCT1 Peptide, Being Developed for the T...
May 8, 2023, 11:00 am
As ocuphire pharma rally gathers steam post-results, what did investors initially miss?
Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc. (US:OCUP) announced its fourt...
April 5, 2023, 10:28 pm
Rxsight, inc. announces full exercise of underwriters’ option to purchase additional shares and closing of its public offering of common stock
ALISO VIEJO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) — RxSight, Inc. (“RxSight®”), an ophthalmic ...
February 14, 2023, 9:05 pm
Bruder healthcare now exclusive licensor of the dry eye drink™ — first and only ophthalmic anti-inflammatory hyper-hydrating drink
The Dry Eye Drink by Bruder The Dry Eye Drink by Bruder ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) — Bruder Healthcare, a Hilco Vision Company, announc...
February 13, 2023, 3:00 pm
Outlook therapeutics® to present at the svb securities global biopharma conference
– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET – ISELIN, N.J., F...
February 7, 2023, 1:05 pm
Skye bioscience hires ophthalmic-focused cro for phase 2a us trial of glaucoma and hypertension treatment
Skye Bioscience Inc (OTCQB:SKYE) has entered into an agreement with Lexitas Pharma Services Inc, a full-service ...
February 2, 2023, 9:12 am
Onl therapeutics receives u.s. fda clearance of investigational new drug application for onl1204 ophthalmic solution
First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, Mich.,...
February 1, 2023, 12:00 pm
Skye bioscience gets positive safety review of sbi-100 oe after phase 1 first cohort
Skye Bioscience Inc (OTCQB:SKYE) said it has received a positive recommendation following a pre-specified data review by the safety review committee (...
January 31, 2023, 7:51 am
Amber ophthalmics announces positive topline phase 2 data evaluating nexagon® for the treatment of persistent corneal epithelial defect (pced)
••Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone••NEXAGON was well-...
January 9, 2023, 12:31 pm
Rxsight, inc. announces preliminary unaudited fourth quarter and full year 2022 financial and operational results
ALISO VIEJO, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic...
January 8, 2023, 9:00 pm
Annexon to present at 41st annual j.p. morgan healthcare conference
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
January 4, 2023, 6:30 am
Rvl pharmaceuticals: a first 'look'
Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only ...
December 30, 2022, 3:30 pm